Catamaran harnesses the natural cancer-fighting properties of NK cells, the power of synthetic biology and innovative non-viral cell engineering to create novel CAR-NK cell therapies
Total raised: $42M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 24.11.2020 | Sofinnova ... | sofinnovap... |
| - | Takeda Ven... | takeda.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.11.2020 | Series A | $42M | - |
Mentions in press and media 10
| Date | Title | Description |
| 10.04.2025 | Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO | BOSTON, Mass., April 10, 2025 – Imbria Pharmaceuticals, Inc., a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, today announced the successful closing of a $57.5 million Ser... |
| 05.04.2022 | Catamaran Bio Appoints Frank Lee as Chair of its Board of Directors | — Appointment of experienced commercial leader brings significant expertise in solid tumor indications targeted by Catamaran’s CAR-NK programs — |
| 26.04.2021 | Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer | CAMBRIDGE, Mass. – April 26, 2021 – Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need, today announced the appointment of Scott Holmes, MS, MBA, as... |
| 24.11.2020 | Catamaran Bio launches with $42M | Catamaran Bio has raised $42 million in a Series A co-led by Sofinnova Partners and Lightstone Ventures. Based in the Boston area, the company is a developer of cell therapies intended to treat solid tumors. Additional Investors SV Health I... |
| 24.11.2020 | Catamaran Bio secures US$ 42 million Series A financing | - |
| 23.11.2020 | Catamaran Bio Raises $42M in Series A Funding | Catamaran Bio, Inc., a Cambridge, Mass. – based biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, launched with $42m in Series A financing. The round was co-led by Sofinnova Partners and Lightstone Ventures,... |
| 23.11.2020 | The Briefing: CoStar Buys Homesnap, Torchy’s Tacos bites into $400M, And More | 5 Shares Email Facebook Twitter LinkedIn Here’s what you need to know today in startup and venture news, updated by the Crunchbase News staff throughout the day to keep you in the know. Subscribe to the Crunchbase Daily CoStar to acquire Ho... |
| 23.11.2020 | Catamaran Bio Launches with $42 Million Financing | Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing. Sofinnova Partners and Lightstone Ventures co-led the Ser... |
| 23.11.2020 | Catamaran Bio Launches with $42M in Series A | CAMBRIDGE, MA, Catamaran Bio has launched with $42 million in Series A financing co-led by Sofinnova Partners and Lightstone Ventures. >> Click here for more funding data on Catamaran Bio >> To export Catamaran Bio funding d... |
| 23.11.2020 | Catamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors | Company brings together scientific founders with leading-edge expertise in NK cells and leadership team with deep cell therapy experience |